Key result
A recombinant VP2 subunit vaccine induced protective maternal antibodies in hens, protecting progeny chickens against virulent infectious bursal disease virus challenge.
Why the study?
Does a recombinant subunit vaccine protect progeny chickens from infectious bursal disease?
Does a recombinant subunit vaccine protect progeny chickens from infectious bursal disease?
A recombinant VP2 subunit vaccine can induce protective maternal antibodies in hens, protecting progeny from infectious bursal disease, and can replace conventional inactivated vaccines.
Supports recombinant VP2 for maternal IBDV protection in poultry; leaves open field efficacy and commercial replacement of inactivated vaccines.
The major protective immunogen of infectious bursal disease virus (IBDV), VP2, was produced in a highly immunogenic form by expression in the yeast Saccharomyces cerevisiae. The recombinant protein, formulated as an oil-emulsion vaccine, induced both virus neutralising and ELISA antibodies in specific pathogen free hens. These antibodies were passed, via the egg yolk, to progeny chickens and protected them against a challenge infection with virulent IBDV. The protective efficacy of maternal antibodies to the recombinant VP2, as assessed by ELISA, was comparable to that of antibodies to the whole virus. The recombinant subunit vaccine induced anamnestic serum antibody responses in hens primed previously with live virus, and hence can replace the conventional inactivated vaccines administered to breeding hens.
No takes yet. Share an insight, caveat, or question.
Fahey et al. (1991) studied Infectious bursal disease. Recombinant VP2 subunit vaccine vs. Whole virus vaccine was evaluated on Induction of virus neutralising and ELISA antibodies, and protection of progeny against virulent IBDV challenge. A recombinant VP2 subunit vaccine induced protective maternal antibodies in hens, protecting progeny chickens against virulent infectious bursal disease virus challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: